The sarcopenia index: A novel measure of muscle mass in lung transplant candidates

Kianoush Kashani, Kumar Sarvottam, Naveen Luke Pereira, Erin F. Barreto, Cassie Kennedy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Frailty, including low muscle mass, is an emerging risk factor for poor outcomes after lung transplant. The sarcopenia index (SI)—(serum creatinine value/cystatin C value) × 100—is a novel blood test to approximate muscle mass. We sought to validate SI among lung transplant patients. Methods: We retrospectively identified adult lung transplant recipients from 2000 through 2012 at our institution who underwent computed tomography within 1 year before transplant and had preserved blood samples. Creatinine and cystatin C values were measured using the samples and used to calculate SI. Muscle mass was estimated by computed tomographic measurement of skeletal muscle cross-sectional surface area (SA) at the L1 to L3 vertebral levels. Correlation between SI and SA was evaluated. Results: Of 28 patients meeting eligibility criteria, most were white (96%) and men (54%). Median (interquartile range) body mass index, SI, and SA were 25.9 (22-30) kg/m2, 106 (91-119), and 157 (113-195) cm2, respectively. The Pearson correlation coefficient between SI and SA was significant at L2 (0.43; P =.02) and L3 (0.41; P =.03). Conclusion: Sarcopenia index is a potentially objective measure for estimating muscle mass that is noninvasive and less expensive. Sarcopenia index could be considered in lung transplant candidate selection following prospective validation in larger cohorts.

Original languageEnglish (US)
Article numbere13182
JournalClinical Transplantation
Volume32
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Sarcopenia
Transplants
Muscles
Lung
Cystatin C
Creatinine
Hematologic Tests
Skeletal Muscle
Body Mass Index
Tomography

Keywords

  • creatinine
  • cystatin C
  • lung transplant
  • muscle mass
  • nutrition
  • sarcopenia index

ASJC Scopus subject areas

  • Transplantation

Cite this

The sarcopenia index : A novel measure of muscle mass in lung transplant candidates. / Kashani, Kianoush; Sarvottam, Kumar; Pereira, Naveen Luke; Barreto, Erin F.; Kennedy, Cassie.

In: Clinical Transplantation, Vol. 32, No. 3, e13182, 01.03.2018.

Research output: Contribution to journalArticle

@article{871b97e00004421cb3dbe03a6bf4c646,
title = "The sarcopenia index: A novel measure of muscle mass in lung transplant candidates",
abstract = "Background: Frailty, including low muscle mass, is an emerging risk factor for poor outcomes after lung transplant. The sarcopenia index (SI)—(serum creatinine value/cystatin C value) × 100—is a novel blood test to approximate muscle mass. We sought to validate SI among lung transplant patients. Methods: We retrospectively identified adult lung transplant recipients from 2000 through 2012 at our institution who underwent computed tomography within 1 year before transplant and had preserved blood samples. Creatinine and cystatin C values were measured using the samples and used to calculate SI. Muscle mass was estimated by computed tomographic measurement of skeletal muscle cross-sectional surface area (SA) at the L1 to L3 vertebral levels. Correlation between SI and SA was evaluated. Results: Of 28 patients meeting eligibility criteria, most were white (96{\%}) and men (54{\%}). Median (interquartile range) body mass index, SI, and SA were 25.9 (22-30) kg/m2, 106 (91-119), and 157 (113-195) cm2, respectively. The Pearson correlation coefficient between SI and SA was significant at L2 (0.43; P =.02) and L3 (0.41; P =.03). Conclusion: Sarcopenia index is a potentially objective measure for estimating muscle mass that is noninvasive and less expensive. Sarcopenia index could be considered in lung transplant candidate selection following prospective validation in larger cohorts.",
keywords = "creatinine, cystatin C, lung transplant, muscle mass, nutrition, sarcopenia index",
author = "Kianoush Kashani and Kumar Sarvottam and Pereira, {Naveen Luke} and Barreto, {Erin F.} and Cassie Kennedy",
year = "2018",
month = "3",
day = "1",
doi = "10.1111/ctr.13182",
language = "English (US)",
volume = "32",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The sarcopenia index

T2 - A novel measure of muscle mass in lung transplant candidates

AU - Kashani, Kianoush

AU - Sarvottam, Kumar

AU - Pereira, Naveen Luke

AU - Barreto, Erin F.

AU - Kennedy, Cassie

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Background: Frailty, including low muscle mass, is an emerging risk factor for poor outcomes after lung transplant. The sarcopenia index (SI)—(serum creatinine value/cystatin C value) × 100—is a novel blood test to approximate muscle mass. We sought to validate SI among lung transplant patients. Methods: We retrospectively identified adult lung transplant recipients from 2000 through 2012 at our institution who underwent computed tomography within 1 year before transplant and had preserved blood samples. Creatinine and cystatin C values were measured using the samples and used to calculate SI. Muscle mass was estimated by computed tomographic measurement of skeletal muscle cross-sectional surface area (SA) at the L1 to L3 vertebral levels. Correlation between SI and SA was evaluated. Results: Of 28 patients meeting eligibility criteria, most were white (96%) and men (54%). Median (interquartile range) body mass index, SI, and SA were 25.9 (22-30) kg/m2, 106 (91-119), and 157 (113-195) cm2, respectively. The Pearson correlation coefficient between SI and SA was significant at L2 (0.43; P =.02) and L3 (0.41; P =.03). Conclusion: Sarcopenia index is a potentially objective measure for estimating muscle mass that is noninvasive and less expensive. Sarcopenia index could be considered in lung transplant candidate selection following prospective validation in larger cohorts.

AB - Background: Frailty, including low muscle mass, is an emerging risk factor for poor outcomes after lung transplant. The sarcopenia index (SI)—(serum creatinine value/cystatin C value) × 100—is a novel blood test to approximate muscle mass. We sought to validate SI among lung transplant patients. Methods: We retrospectively identified adult lung transplant recipients from 2000 through 2012 at our institution who underwent computed tomography within 1 year before transplant and had preserved blood samples. Creatinine and cystatin C values were measured using the samples and used to calculate SI. Muscle mass was estimated by computed tomographic measurement of skeletal muscle cross-sectional surface area (SA) at the L1 to L3 vertebral levels. Correlation between SI and SA was evaluated. Results: Of 28 patients meeting eligibility criteria, most were white (96%) and men (54%). Median (interquartile range) body mass index, SI, and SA were 25.9 (22-30) kg/m2, 106 (91-119), and 157 (113-195) cm2, respectively. The Pearson correlation coefficient between SI and SA was significant at L2 (0.43; P =.02) and L3 (0.41; P =.03). Conclusion: Sarcopenia index is a potentially objective measure for estimating muscle mass that is noninvasive and less expensive. Sarcopenia index could be considered in lung transplant candidate selection following prospective validation in larger cohorts.

KW - creatinine

KW - cystatin C

KW - lung transplant

KW - muscle mass

KW - nutrition

KW - sarcopenia index

UR - http://www.scopus.com/inward/record.url?scp=85044639144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044639144&partnerID=8YFLogxK

U2 - 10.1111/ctr.13182

DO - 10.1111/ctr.13182

M3 - Article

C2 - 29274246

AN - SCOPUS:85044639144

VL - 32

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 3

M1 - e13182

ER -